aromatase 2004, edinburgh, uk, 6-8 september 2004芳香化酶2004年爱丁堡,英国,2004年9月6 - 8.pdfVIP

Available online /content/7/1/E2 Meeting report Aromatase 2004, Edinburgh, UK, 6–8 September 2004 William R Miller and Alexey Larionov Edinburgh Breast Unit, Western General Hospital, Edinburgh, UK Corresponding author: William R Miller, ler@ed.ac.uk Published: 2 November 2004 Breast Cancer Res 2005, 7:E2 (DOI 10.1186/bcr964) © 2005 BioMed Central Ltd Abstract Aromatase is the key enzyme involved in oestrogen biosynthesis. Oestrogens not only influence normal development and function but are also implicated in the aetiology and progression of many diseases. Over recent years rational drug design programmes have led to the development of agents that specifically and potently inhibit aromatase. The multidisciplinary international symposium Aromatase 2004 provided a forum in which basic scientists, translational researchers and practising clinicians reviewed latest results, exchanged opinions, and defined future needs for the regulation of oestrogen biosynthesis and the use of aromatase inhibitors. Keywords: aromatase, breast cancer, hormone dependent disease, inhibitors, oestrogen biosynthesis Introduction phenotype mirrored clinical features in a man with Aromatase 2004 was held in Edinburgh, Scotland on 6–8 aromatase deficiency who developed type 2 diabetes, September 2004. More than 200 delegates and 30 truncal obesity, acantosis nigricans and hepatic steatosis. invited speakers formed a faculty drawn from 23 countries. The programme embraced basic science, translational Describi